ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Bendell on the Future of Regorafenib for Patients With CRC

Johanna C. Bendell, MD
Published: Wednesday, Nov 15, 2017



Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Further studies need to be done to determine the best dosage for regorafenib because most patients cannot tolerate the current dose, says Bendell.

A current trial conducted by researchers out of Mayo Clinic is comparing the full dosage to a lower dosage to see if tolerability will translate into increased progression-free survival, explains Bendell.


Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Further studies need to be done to determine the best dosage for regorafenib because most patients cannot tolerate the current dose, says Bendell.

A current trial conducted by researchers out of Mayo Clinic is comparing the full dosage to a lower dosage to see if tolerability will translate into increased progression-free survival, explains Bendell.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x